GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Simcere Pharmaceutical Group Ltd (STU:S2P) » Definitions » Sale Of Investment

Simcere Pharmaceutical Group (STU:S2P) Sale Of Investment : €12.3 Mil (TTM As of Jun. 2024)


View and export this data going back to 2022. Start your Free Trial

What is Simcere Pharmaceutical Group Sale Of Investment?

Simcere Pharmaceutical Group's sale of investment for the six months ended in Jun. 2024 was €6.0 Mil. It means Simcere Pharmaceutical Group gained €6.0 Mil from selling investments. Simcere Pharmaceutical Group's sale of investment for the trailing twelve months (TTM) ended in Jun. 2024 was €12.3 Mil.

Compared with last quarter (€6.3 Mil in Dec. 2023 ), Simcere Pharmaceutical Group gained less money from selling investments in Jun. 2024 (€6.0 Mil).


Simcere Pharmaceutical Group Sale Of Investment Historical Data

The historical data trend for Simcere Pharmaceutical Group's Sale Of Investment can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Simcere Pharmaceutical Group Sale Of Investment Chart

Simcere Pharmaceutical Group Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Sale Of Investment
Get a 7-Day Free Trial 96.11 62.68 111.61 121.89 -

Simcere Pharmaceutical Group Semi-Annual Data
Dec17 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24
Sale Of Investment Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 16.83 116.00 6.31 5.96 -

Simcere Pharmaceutical Group Sale Of Investment Calculation

Sale of Investments represents cash inflow on the sale of investments in securities.

Sale Of Investment for the trailing twelve months (TTM) ended in Jun. 2024 adds up the semi-annually data reported by the company within the most recent 12 months, which was €12.3 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Simcere Pharmaceutical Group Sale Of Investment Related Terms

Thank you for viewing the detailed overview of Simcere Pharmaceutical Group's Sale Of Investment provided by GuruFocus.com. Please click on the following links to see related term pages.


Simcere Pharmaceutical Group Business Description

Traded in Other Exchanges
Address
No. 699-18, Xuanwu Road, Xuanwu District, Jiangsu, Nanjing, CHN, 210042
Simcere Pharmaceutical Group Ltd is engaged in the R&D, production, and commercialization of pharmaceuticals focused on generic pharmaceuticals. It has a diversified product portfolio focused on therapeutic areas, including, oncology (including cell therapy), nervous system diseases, autoimmune diseases, and antiinfection. The company's products include Endostar, Enweida, Iremod, Sanbexin and Others.

Simcere Pharmaceutical Group Headlines

No Headlines